Spasticity Resources - Zanaflex Insurance Coverage

Resources

Insurance Coverage and Reimbursement Made Simple

The Zanaflex Capsules^® Assistance Program is designed to help you work through the insurance reimbursement process with as few complications as possible. It’s simple:

Call the Zanaflex Capsules^® Assistance Program
toll-free at 1-800-999-6673 ext.240 from 10am to 6pm Eastern Time, Monday through Friday

Have the following information ready when calling:

Contact information
Name of insurance plan
Insurance plan membership number
Date of birth
Physician's name and address
Physician's phone number

Knowledgeable patient advocates will assist you with a variety of questions concerning your Zanaflex Capsules^® prescription including providing assistance with claim forms and helping to obtain insurance healthcare coverage.

Don't Have Health Insurance?

There is a program to help people who do not have insurance and whose income falls within specific guidelines. The patient advocates at the toll-free number listed above will be able to help you with the application process for this program.

Acorda Therapeutics, Inc. the makers of Zanaflex Capsules^®, is committed to protecting your privacy. Any of the information you provide to the patient advocates will not be sold or used for any marketing solicitations by Acorda Therapeutics, Inc. or any of its affiliates. See our Privacy Policy.

Please see below for Important Safety Information.

Be sure you received what your doctor ordered.

Zanaflex Capsules® (tizanidine hydrochloride) is a short-acting drug indicated for the management of spasticity. Because of the short duration of effect, treatment with Zanaflex Capsules® (tizanidine hydrochloride) should be reserved for those daily activities and times when relief of spasticity is most important.

Important Safety Information:

Use with fluvoxamine or ciprofloxacin is contraindicated and results in significant increases in tizanidine plasma levels.
There is a limited data base for chronic use of single doses above 8 mg and multiple doses above 24 mg per day.
Tizanidine is an alpha2-adrenergic agonist and can produce hypotension. In a single-dose study where patients were not titrated, two-thirds of patients given 8 mg of Zanaflex experienced hypotension, which may be minimized by titration of dose. The hypotensive effect is dose related and has been measured following single doses of 2 mg or more.
Tizanidine occasionally causes liver injury, most often of the hepatocellular type.
Patients should be advised that sedation may interfere with daily activities. These effects appear to be dose related.
Visual hallucinations or delusions occurred in 3% (5/170) of study patients in two North American clinical trials.
Use with caution in hepatic or renally impaired patients.
Use with oral contraceptives results in 50% decrease in tizanidine clearance.
To discontinue therapy, taper the dose in patients receiving high doses over long time periods to reduce the risk of hypertension, tachycardia and hypertonia.
In vitro studies indicate that neither tizanidine nor the major metabolites are likely to affect the metabolism of other drugs metabolized by cytochrome P450 isoenzymes.
Most common adverse events with tizanidine include dry mouth (49%), somnolence (48%), asthenia [weakness, fatigue and/or tiredness] (41%), dizziness (16%) and increased ALT (5%). Other adverse events include UTI, infection and constipation.
Food has complex effects on tizanidine pharmacokinetics, which differ for the different formulations. These pharmacokinetic differences may result in clinically significant differences when switching formulations, or changing administration during a fed or fasted state. These changes may result in increased adverse events or a delayed/more rapid onset of activity, depending on the nature of the switch.

For Full Prescribing Information - Click Here Information For Patients Guide - Click Here

Getting Started

Resources

Insurance Coverage and Reimbursement Made Simple

Don't Have Health Insurance?